Form 4: Xeris Biopharma Director Jeffrey Sherman Awarded 50,000 Restricted Stock Units

Xeris Biopharma Holdings, Inc. Director Jeffrey W. Sherman was granted 50,000 restricted stock units, vesting by June 2026, as disclosed in a recent SEC Form 4 filing.

Summary

• Jeffrey W. Sherman, a Director of Xeris Biopharma Holdings, Inc. (XERS), was awarded 50,000 shares of common stock on June 4, 2025.
• These shares were granted as a Restricted Stock Unit (RSU) award under the Company's 2018 Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of the Company's common stock.
• The RSU award vests in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.
• Following this transaction, Mr. Sherman directly beneficially owns 214,380 shares of common stock.
• Additionally, 5,400 shares are indirectly beneficially owned through the JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001, for which Mr. Sherman disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a director is generally a positive signal, indicating alignment of interests and retention efforts, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The award of 50,000 restricted stock units to a director aligns the director's interests with long-term shareholder value, as the shares vest over time.
• Restricted stock unit awards are a common form of equity compensation used to attract and retain key personnel.

Negatives

• No negative information, such as insider selling, was reported in this filing.

Risks

• No specific risks were mentioned in this Form 4 filing, which primarily reports changes in beneficial ownership.

Future Outlook

The 50,000 restricted stock units awarded to Director Jeffrey W. Sherman are scheduled to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders, indicating a future commitment and alignment of interests.

Industry Context

This Form 4 filing reflects a standard practice of equity compensation for directors in the biopharmaceutical industry, aiming to incentivize long-term commitment and performance. Such awards are common across publicly traded companies to align management and director interests with shareholder returns.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's interests with shareholders by tying a portion of their compensation to the company's long-term stock performance.
• Employees: While not directly impacting employees, this type of equity compensation for directors sets a precedent for how the company values and incentivizes its leadership.

Next Steps

• The 50,000 restricted stock units are expected to vest in full upon the earlier of June 4, 2026, or the date of the Company's next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Xeris Biopharma Holdings, XERS, SEC Form 4, Restricted Stock Unit, RSU, Insider Ownership, Director Compensation, Equity Award, Beneficial Ownership, Stock Plan